natgillin/translations-raw huggingface dataset:
The study met the pre-defined criteria for non-inferiority of NeuroBloc compared to Botulinum Toxin Type A, both in terms of mean TWSTRS total score at week 4 after first and second treatment sessions, and in terms of duration of effect. 
Študija je izpolnjevala vnaprej definirana merila za neinferiornost zdravila NeuroBloc v primerjavi z botulinskim toksinom vrste A, tako glede rezultata povprečne celotne TWSTRS v 4. tednu po prvem in drugem ciklu zdravljenju, kot glede trajanja učinka.
P-Value* * Analysis of covariance, two-tailed tests, a = 0.05 
Srednja vrednost - 4. teden 47,9 Vrednost P* * analiza kovariance, dvostranski testi, a = 0,05
2500 U 
2.500 E
Following NeuroBloc treatment, all patients and caregivers should be advised to seek medical attention for respiratory difficulties, choking or any new or worsening dysphagia. 
Po zdravljenju z zdravilom NeuroBloc je treba vse bolnike in skrbnike obvestiti, da naj v primeru težav pri dihanju, v primeru dušenja ali pojava nove disfagije ali njenega poslabšanja poiščejo zdravniško pomoč.
The second study enrolled patients who continued to respond to type A toxin (A-responders). 
V drugi študiji so vključili bolnike, ki so se še vedno odzivali na toksin vrste A (A-dovzetni).
The non-inferiority of NeuroBloc compared to Botulinum Toxin Type A was further supported by a responder analysis where similar percentages of subjects showed improvement in the TWSTRS score at Week 4 of Session 1 (86% NeuroBloc and 85% Botox), and a similar proportion of subjects experienced at least a 20% decrease from baseline in the TWSTRS score at Week 4 of Session 1 (51% NeuroBloc, 47% Botox). 
Enakovrednost zdravila NeuroBloc glede na butulinski toksin vrste A je nadalje podprla analiza responderjev, v kateri so različni odstotni deleži bolnikov pokazali izboljšanje rezultata TWSTRS v 4. tednu 1. cikla (86 % NeuroBloc in 85 % Botox), podoben delež bolnikov pa je pokazal vsaj 20odstotno zmanjšanje rezultata TWSTRS od izhodišča v 4. tednu 1. seje (51 % NeuroBloc, 47 % Botox).
Immunogenicity data from three long-term clinical studies indicate that approximately one third of patients develop antibodies, as determined by the mouse neutralisation/ mouse protection assay dependent on duration of exposure. 
Podatki o imunogenosti iz treh dolgoročnih kliničnih študij kažejo, da se pri približno eni tretjini bolnikov razvijejo protitelesa, kot je bilo ugotovljeno s testom nevtralizacije pri miših/zaščite miši, odvisno od trajanja izpostavljenosti.
The mechanism by which muscle paralysis is reversed over time remains unknown, but may be associated with the intraneuronal turnover of the affected protein and/or sprouting of the nerve ending. 
Mehanizem, zaradi katerega se mišična paraliza čez čas povrne v normalno stanje, ni znan, vendar je lahko povezan z intranevralno pretvorbo (turnover - nastajanjem in razkrojem) prizadete beljakovine in/ali rastjo živčnega končiča.
A. MANUFACTURER OF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURER RESPONSIBLE FOR BATCH RELEASE 
A. IZDELOVALEC BIOLOŠKE ZDRAVILNE UČINKOVINE in IZDELOVALEC, ODGOVOREN ZA SPROŠČANJE SERIJ
Produced in Clostridium botulinum Serotype B (Bean Strain) cells. 
Izdelano v celicah Clostridium botulinum serotipa B (sev, izoliran iz fižola).
Nervous system disorders dry mouth, headache torticollis (worsening from baseline), taste perversion 
Bolezni živčevja suha usta, glavobol tortikolis (poslabšanje od izhodišča), popačeno okušanje
Other medicines and NeuroBloc 
Druga zdravila in zdravilo NeuroBloc
From a microbiological point of view, unless the method of opening/dilution precludes the risk of microbial contamination the product should be used immediately. 
Z mikrobiološkega vidika je treba zdravilo uporabiti takoj, razen kadar način odpiranja/redčenja preprečuje tveganje onesnaženja zdravila z mikrobi.
STUDY 2 (A-Responsive Patients) 
ŠTUDIJA (bolniki, dovzetni za A)
This is because NeuroBloc can affect the way some medicines work and other medicines can also affect the way NeuroBloc works. 
Zdravilo NeuroBloc namreč vpliva na delovanje nekaterih drugih zdravil, nekatera druga zdravila pa lahko vplivajo na delovanje zdravila NeuroBloc.
Single dose pharmacology studies in cynomolgus monkeys have shown no effects other than the anticipated dose-dependent paralysis of injected muscles, together with some diffusion of toxin at high doses producing similar effects in neighbouring non-injected muscles. 
Farmakološke raziskave enkratnih odmerkov na opicah vrste Macaca fascicularis niso pokazale učinkov, razen od odmerka odvisne pričakovane paralize mišic, v katere so injicirali zdravilo, ter nekaj difuzije toksina pri visokih odmerkih, kar je povzročilo podobne učinke v bližnjih mišicah, v katere zdravila niso injicirali.
Extracellular binding of the toxin to specific acceptors on motor nerve terminals Internalisation and release of the toxin into the cytosol of the nerve terminals Inhibition of acetylcholine release from nerve terminals at the neuromuscular junction 
zunajcelična vezava toksina na specifične akceptorje na končičih motoričnih nevronov; vstop in sproščanje toksina v citosol živčnih končičev; inhibicija sproščanja acetilholina iz živčnih končičev v nevromuskularno špranjo.
NeuroBloc is a neuromuscular blocking agent. 
Zdravilo NeuroBloc je nevromuskularni blokator.
When injected directly into a muscle, NeuroBloc causes a localised paralysis that gradually reverses over time. 
Po neposrednem injiciranju v mišico zdravilo NeuroBloc povzroči lokalizirano paralizo, ki se čez čas postopoma povrne v normalno stanje.
Once diluted, the medicinal product must be used immediately as the formulation does not contain a preservative. 
Razredčeno zdravilo morate uporabiti takoj, ker pripravek ne vsebuje konzervansa.
The safety of NeuroBloc when used to treat other conditions is not known: some side effects may be fatal. 
Varnost zdravila NeuroBloc za zdravljenje drugih bolezni ni znana; nekateri neželeni učinki so lahko za bolnika smrtni.
Patients with neuromuscular disorders may be at increased risk of clinically significant effects including severe dysphagia and respiratory compromise from typical doses of NeuroBloc (see section 4.3). 
Bolnike z živčnomišičnimi boleznimi lahko ogrožajo klinično pomembni učinki, med drugim težka disfagija in prizadetost dihanja pri običajnih odmerkih zdravila NeuroBloc (glejte poglavje 4.3).
It is unknown whether Botulinum Toxin Type B is excreted in human breast milk. 
Ni znano, ali se botulinski toksin vrste B izloča v materino mleko.
Studies have not been carried out in patients with hepatic or renal impairment. 
Študije pri bolnikih z okvarjenim delovanjem jeter ali ledvic niso bile opravljene.
Following local intramuscular injection of NeuroBloc serious adverse events that may have been due to systemic effects of Botulinum Toxin Type B, were observed in 12% of adverse reaction cases reported during the post-marketing experience (including the following adverse reactions: dry mouth, dysphagia and blurred vision). 
Po lokalnem intramuskularnem injiciranju zdravila NeuroBloc so opazili resne neželene učinke, ki bi lahko bili posledica sistemskih učinkov botulinskega toksina vrste B, pri 12 % primerov neželenih učinkov, o katerih so poročali po uvedbi zdravila na trg (vključno z naslednjimi neželenimi učinki: suha usta, disfagija in zamegljen vid).
Place the absorbed toxin in an autoclave bag, seal it and process as Medical Biohazardous Waste in accordance with local requirements. 
Absorbirani toksin dajte v vrečko za avtoklav, zaprite in obdelajte kot biološko nevaren medicinski odpadek v skladu z lokalnimi predpisi.
Marketing Authorisation Holder: Sloan Pharma S.à.r.l. 
Imetnik dovoljenja za promet z zdravilom: Sloan Pharma S.à.r.l.
if you are allergic to Botulinum Toxin Type B or any of the other ingredients of NeuroBloc (listed in section 6) if you have other problems with your nerves or muscles, such as amyotrophic lateral sclerosis (Lou Gehrig's disease), peripheral neuropathy, myasthenia gravis or Lambert-Eaton syndrome (muscle weakness or numbness or pain) if you have been experiencing shortness of breath or difficulty swallowing 
če ste alergični na botulinski toksin vrste B ali katero koli sestavino tega zdravila (navedeno v poglavju 6); če imate druge težave z živci ali mišicami, na primer amiotrofično lateralno sklerozo (Lou Gehrigovo bolezen), periferno nevropatijo, miastenijo gravis ali Lambert-Eatonov sindrom (šibkost mišic ali odrevenelost ali bolečino); če se vam pojavi oteženo dihanje ali ste imeli težave s požiranjem.
The secondary endpoints included Visual Analogue Scales (VAS) to quantify the Patient Global Assessment of change and the Physician Global Assessment of change, both from baseline to Week 4. 
Sekundarni zaključki so vsebovali še vizualno analogno lestvico (VAS - Visual Analogue Scale) za kvantifikacijo bolnikove splošne ocene spremembe in zdravnikovo splošno oceno spremembe od izhodiščne vrednosti do 4. tedna.
Pack size of 1. 
Velikost pakiranja je po 1 vialo.
The effect of administering different botulinum neurotoxin serotypes concurrently is unknown. 
Učinek sočasne uporabe različnih serotipov nevrotoksina botulina ni znan.
0.5 ml, 1 ml or 2 ml solution in a 3.5 ml Type I glass vial, with siliconised butyl rubber stoppers oversealed by aluminium crimped caps. 
0,5 ml, 1 ml ali 2 ml raztopine v 3,5 ml velikih steklenih vialah vrste I, z zamaški iz butilne gume, prevlečenimi s silikonom, zaprtimi z aluminijastimi nagubanimi zaporkami.
For storage conditions after dilution of the medicinal product, see section 6.3. 
Za pogoje shranjevanja po redčenju zdravila glejte poglavje 6.3.
In addition to improved function as demonstrated by a reduction in TWSTRS-total score, treatment with NeuroBloc was associated with a significant reduction in TWSTRS-Pain and pain VAS scores at each treatment session at weeks 4, 8 and 12 relative to baseline. 
Poleg izboljšanja funkcije, dokazanega z zmanjšanjem rezultata celotne TWSTRS in bolečinske VAS, je bilo zdravljenje z zdravilom NeuroBloc povezano z značilnim zmanjšanjem rezultatov bolečinske TWSTRS in bolečinske VAS pri vsakem ciklu zdravljenja v 4., 8. in 12. tednu glede na izhodišče.
The most commonly reported adverse reactions associated with NeuroBloc treatment were dry mouth, dysphagia, dyspepsia, and injection site pain. 
Neželeni učinki, povezani z zdravljenjem z zdravilom NeuroBloc, o katerih so najpogosteje poročali, so bili suha usta, disfagija, dispepsija in bolečina na mestu injiciranja.
If the NeuroBloc solution is not clear and colourless/light yellow or if the vial appears damaged, the product should not be used, but discarded as Medical Biohazardous Waste in accordance with local requirements. 
Če raztopina zdravila NeuroBloc ni bistra in brezbarvna/svetlorumena ali če je viala videti poškodovana, zdravila ne smete uporabiti, ampak ga zavrzite kot biološko nevaren medicinski odpadek v skladu z lokalnimi predpisi.
Neurobloc may impair the ability to drive or operate machinery in case of adverse reactions such as muscle weakness and eye disorders (blurred vision, eyelid ptosis). 
Zdravilo NeuroBloc lahko zmanjša sposobnost vožnje ali upravljanja s stroji v primeru neželenih učinkov, kot so mišična šibkost in očesne motnje (zamegljen vid, ptoza vek).
Decontaminate any spill with 10% caustic solution, or sodium hypochlorite (household chlorine bleach -2 ml (0.5%): 1 litre water) solution. 
Sleherno izlitje dekontaminirajte z 10-odstotno kavstično raztopino ali raztopino natrijevega klorata (gospodinjsko klorovo belilo - 2 ml (0,5 %) : 1 liter vode).
What NeuroBloc is and what it is used for What you need to know before you use NeuroBloc How to use NeuroBloc 
Kaj je zdravilo NeuroBloc in za kaj ga uporabljamo Kaj morate vedeti, preden boste uporabili zdravilo NeuroBloc Kako uporabljati zdravilo NeuroBloc Možni neželeni učinki
Read package leaflet for special precautions for handling, in-use storage and disposal. 
Za posebne varnostne ukrepe pri ravnanju, shranjevanju med uporabo in odstranjevanju preberite navodilo za uporabo.
The mechanism of action of NeuroBloc in blocking neuromuscular conduction occurs by a three-step process: 
Način delovanja zdravila NeuroBloc pri blokiranju nevromuskularne prevodnosti poteka v treh stopnjah:
These studies have demonstrated the activity of NeuroBloc in both treatment-naïve patients, and patients who have previously received treatment with Botulinum Toxin Type A, including those that were considered clinically resistant to Botulinum Toxin Type A. 
Te študije so dokazale delovanje zdravila NeuroBloc tako pri bolnikih, ki se z njim še niso zdravili, kot pri bolnikih, ki so se predhodno že zdravili z botulinskim toksinom vrste A, vključno s tistimi, ki so jih imeli za klinično rezistentne proti botulinskemu toksinu vrste A.
NeuroBloc is indicated for the treatment of cervical dystonia (torticollis) in adults. 
Zdravilo NeuroBloc je indicirano za zdravljenje cervikalne distonije (tortikolisa) pri odraslih.
A further randomised, multicentre, double-blind study was conducted to compare the efficacy of NeuroBloc (10,000 U) to Botulinum Toxin Type A (150 U) in patients with cervical dystonia who have never previously received a botulinum toxin product. 
Izvedena je bila dodatna randomizirana, multicentrična, dvojno slepa študija IV. faze zaradi primerjave učinkovitosti zdravila NeuroBloc (10.000 E) z botulinskim toksinom vrste A (150 E) pri bolnikih s cervikalno distonijo, ki nikoli prej niso uporabljali zdravil z botulinskim toksinom.
If you have further questions, please ask your doctor or pharmacist. 
Če imate dodatna vprašanja, se posvetujte s svojim zdravnikom ali farmacevtom.
It contains the active ingredient ‘Botulinum Toxin Type B'. 
Vsebuje zdravilno učinkovino 'botulinski toksin vrste B'.
Justification for not including Braille accepted. 
Sprejeta je utemeljitev, da Braillova pisava ni potrebna.
However, the clinical relevance of the presence of antibodies as determined by the mouse neutralisation/ mouse protection assay is uncertain. 
Vendar je klinični pomen prisotnosti protiteles, ugotovljen s testom nevtralizacije pri miših/zaščite miši, dvomljiv.
For instructions on dilution of the product before administration, see section 6.6. 
Za navodila glede redčenja zdravila pred dajanjem glejte poglavje 6.6.
In non clinical experiments, NeuroBloc solution has been diluted up to 6-fold without any resulting change in potency. 
V predkliničnih poskusih so raztopino zdravila NeuroBloc razredčili do šestkrat, ne da bi se jakost kaj spremenila.
This is where you have contractions of your neck or shoulder muscles that you cannot control. 
Pri cervikalni distoniji imate krče mišic vratu in/ali ramen, ki jih ne morete nadzorovati.
Both studies enrolled adult patients (³ 18 years) who had a history of receiving Botulinum Toxin Type A. The first study enrolled patients who were clinically resistant to type A toxin (A-non responders), confirmed by a Frontalis Type A test. 
Obe študiji sta vključevali odrasle bolnike (stari 18 let in več), ki so v preteklosti prejemali botulinski toksin vrste A. V prvi študiji so vključili bolnike, ki so bili klinično rezistentni na toksin vrste A (A-nedovzetni), kar je bilo potrjeno s testom vrste A Frontalis.
United Kingdom 
Združeno kraljestvo in
The potency of this medicinal product is expressed in NeuroBloc 5000 U/ml. 
Jakost tega zdravila se izraža v enotah NeuroBloc 5.000 E/ml.
Talk to your doctor or pharmacist before using NeuroBloc: if you have a bleeding problem such as haemophilia if you have lung problems if you have difficulty swallowing. 
Pred začetkom uporabe zdravila NeuroBloc se posvetujte z zdravnikom ali farmacevtom: - če imate motnje krvavenja, kot je hemofilija, - če imate težave s pljuči, - če imate težave s požiranjem.
In the fertility studies the NOAEL was 300 U/kg/day for general toxicity in both males and females and 1000 U/kg/day for fertility and reproductive performance. 
Pri študijah plodnosti je bila vrednost NOAEL 300 E/kg/dan za splošno toksičnost tako pri samcih kot samicah ter 1000 E/kg/dan za plodnost in sposobnost razmnoževanja.
You may get a dry mouth and it might become difficult to swallow. 
Lahko opazite suha usta in oteženo požiranje.
Within its shelf-life, the product may be removed from the refrigerator for one single period of up to 3 months at a temperature not above 25°C without being refrigerated again. 
Do preteka roka uporabnosti smete vzeti zdravilo iz hladilnika za eno samo obdobje, ki ne sme biti daljše od 3 mesecev, pri temperaturi, ki ne presega 25 °C, ne da bi ga spet ohladili.
General disorders and administration site conditions injection site pain neck pain influenza like illness 
Splošne težave in spremembe na mestu aplikacije bolečine na mestu injiciranja bolečine v vratu gripi podobna bolezen
Table 1 Efficacy Results from Phase III NeuroBloc Studies STUDY 1 (A-Resistant Patients) 
Preglednica 1 Rezultati učinkovitosti zdravila NeuroBloc v študijah III faze 1.
Dysphagia has been reported following injection to sites other than the cervical musculature. 
O disfagiji poročajo po injiciranju v druga mesta, kot je vratno mišičje.
Two Phase III randomised, multicentre, double-blind, placebo-controlled studies were conducted in patients with cervical dystonia. 
Pri bolnikih s cervikalno distonijo so izvedli dve randomizirani, multicentrični, dvojno slepi študiji III faze, kontrolirani s placebom.
The following effects have also been reported during post marketing use: abnormal accommodation, ptosis, vomiting, constipation, flu-like symptoms, asthenia, angioedema, rash, urticaria and pruritus. 
V času po uvedbi zdravila na trg poročajo tudi o naslednjih učinkih: abnormalna akomodacija, ptoza, bruhanje, zaprtost, gripi podobni simptomi, astenija, angioedem, izpuščaj, urtikarija in pruritus.
The extent and time course of seroconversion were similar in patients with prior toxin A exposure and those who were toxin A naïve, and between toxin A resistant and toxin A responsive patients. 
Obseg in časovni potek serokonverzije sta bila podobna pri bolnikih s predhodno izpostavljenostjo toksinu A in pri tistih, ki toksinu A predhodno niso bili izpostavljeni, kot tudi pri bolnikih, rezistentnih proti toksinu A, in pri bolnikih, odzivnih na toksin A.
NeuroBloc injected intramuscularly produces localised muscle weakness by chemical denervation. 
Intramuskularno injicirano zdravilo NeuroBloc s kemično denervacijo povzroča lokalizirano šibkost mišic.
NeuroBloc is used to treat an illness called cervical dystonia (torticollis). 
Zdravilo NeuroBloc se uporablja za zdravljenje bolezni, ki se imenuje cervikalna distonija (tortikolis).
Common (may affect up to 1 in 10 people) blurred vision or drooping of your upper eyelid indigestion or being sick (vomiting) constipation neck pain feeling weak, pain or stiff muscles around your body loss of strength or energy changes in the taste of your food and drink changes in the sound of your voice flu-like symptoms 
prebavne težave ali bruhanje, - zaprtost, - bolečina v vratu, - občutek šibkosti, bolečine ali okorele mišice po telesu, - izguba moči ali energije, - spremembe v okusu hrane in pijače, - spremembe zvoka vašega glasu, - gripi podobni simptomi.
Individuals with known neuromuscular diseases (e.g. amyotrophic lateral sclerosis or peripheral neuropathy) or known neuromuscular junctional disorders (e.g. myasthenia gravis or Lambert-Eaton syndrome) must not be given NeuroBloc. 
Osebam z znano nevromuskularno boleznijo (npr. amiotrofično lateralno sklerozo ali periferno nevropatijo) ali znano boleznijo nevromuskularnega stika (npr. miastenijo gravis ali EatonLambertovim sindromom) zdravila NeuroBloc ne smete dajati.
Lack of interchangeability between botulinum toxin products The initial starting dose of 10,000 U (or 5000 U) is relevant only to NeuroBloc (Botulinum Toxin Type B). 
Nezamenljivost zdravil, ki vsebujejo botulinski toksin Začetni odmerek 10.000 E (ali 5.000 E) velja le za zdravilo NeuroBloc (botulinski toksin vrste B).
5 years, as packaged for sale. 
5 leta v originalni ovojnini.
If botulism is clinically suspected, hospitalisation for the monitoring of respiratory function (incipient respiratory failure) may be required. 
Če obstaja klinični sum za botulizem, bo morda zaradi spremljanja dihalnih funkcij (začetne stopnje dihalne odpovedi) potrebna hospitalizacija.
Tabulated list of adverse reactions 
Tabelarni seznam neželenih učinkov
How to use NeuroBloc 
Kako uporabljati zdravilo Neurobloc
In long term clinical studies, the average dosing frequency was approximately every 12 weeks, however this may vary between subjects, and a proportion of patients maintained a significant improvement relative to baseline for 16 weeks or longer. 
V dolgoročnih kliničnih študijah je bila povprečna pogostnost odmerjanja približno na 12 tednov, vendar se lahko to spreminja od bolnika do bolnika.
Co-administration of NeuroBloc and aminoglycosides or agents interfering with neuromuscular transmission (e.g. curare-like compounds) should be considered with caution. 
Pri sočasni uporabi zdravila NeuroBloc in aminoglikozidov ali učinkovin, ki ovirajo nevromuskularni prenos (npr. spojine, podobne kurareju), morate biti previdni.
In rabbits, the NOAEL was 0.1 U/kg/day for maternal effects and 0.3 U/kg/day for foetal effects. 
Pri kuncih je bila vrednost NOAEL 0,1 E/kg/dan za učinke na brejo mater in 0,3 E/kg/dan za učinke na plod.
In the development studies, the No Observed Adverse Effect Dose Level (NOAEL) in rats was 1000 U/kg/day for maternal effects and 3000 U/kg/day for foetal effects. 
V študijah razvoja je bila raven brez vidnega neželenega učinka (NOAEL - No Observed Adverse Effect Dose Level) pri podganah 1.000 E/kg/dan za učinke na brejo mater in 3.000 E/kg/dan za učinke na plod.
NeuroBloc must only be administered by intramuscular injection. 
Zdravilo NeuroBloc se sme dajati samo v obliki intramuskularnih injekcij.
Mean at Week 4 P-Value* 
Srednja vrednost - 4. teden 39,5 Vrednost P*
NeuroBloc will be given to you by a doctor with specialist experience in the treatment of cervical dystonia and in the use of botulinum toxins. 
Zdravilo NeuroBloc vam bo dajal zdravnik specialist, izkušen v zdravljenju cervikalne distonije in uporabi botulinskih toksinov.
If you are given more NeuroBloc than you should if you have been given more NeuroBloc than you need, some of your muscles that were not injected may feel weak or you may develop symptoms away from the injected muscles, like difficulty in swallowing or breathing. 
Če vam dajo več zdravila NeuroBloc, kot je potrebno, vam lahko oslabijo nekatere mišice, v katere vam niso ničesar injicirali, ali pa se vam lahko razvijejo simptomi, povezani s širjenjem botulinskega toksina v druge telesne dele z mesta, kamor je bila dana injekcija, na primer oteženo požiranje ali dihanje.
Neuromuscular effects related to spread of toxin, distant from the site of administration have been reported (see section 4.8). 
Poročajo o učinkih na nevromuskulaturo v zvezi s širjenjem toksina na mestih, ki so oddaljena od mesta odmerjanja (glejte poglavje 4.8).
What NeuroBloc looks like and contents of the pack 
Izgled zdravila NeuroBloc in vsebina pakiranja
Such dilutions with sodium chloride should be done in a syringe, pulling out the desired amount of NeuroBloc into the syringe first, and then adding sodium chloride to the syringe. 
Zdravilo razredčite z natrijevim kloridom v brizgi, najprej izvlecite potrebno količino zdravila NeuroBloc v brizgo, nato pa v brizgo dodajte natrijev klorid.
It is possible that cervical dystonia could become worse after you have had your injection. 
Možno je, da se bo potem, ko boste dobili injekcijo, cervikalna distonija poslabšala.
Patient Global 
Splošna ocena bolnika
The other ingredients are disodium succinate, sodium chloride, human serum albumin solution, hydrochloric acid (for pH adjustment) and water for injections. 
Druge sestavine zdravila so dinatrijev sukcinat, natrijev klorid, raztopina humanega serumskega albumina, klorovodikova kislina (za uravnavanje pH) in voda za injekcije.